CRISPR Therapeutics AG vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
5.2
Bearish
Overall
6.7
Neutral
Quality
Health
Growth
Valuation
Sentiment
CRSP
Clean balance sheet with low leverage (0.1× debt-to-equity).
⚠ low return on equity (-30%).
MRK
Forward P/E of 11.5× is low relative to sector peers.
Analyst Consensus
BUY
Target $83.35 (+61.4%)
23 analysts
BUY
Target $129.74 (+15.7%)
27 analysts
Fundamentals
CRSP
MRK
—
Trailing P/E
31.5×
-12.9×
Forward P/E
11.5×
0.0%
Profit Margin
13.6%
0.0%
Gross Margin
76.6%
-30.2%
ROE
—
-97.6%
Revenue Growth
4.9%
—
Earnings Growth
—
1.79
Beta
0.28
—
Price / Book
—
$5.0B
Market Cap
$277.0B
$33 – $78
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →